Gliknik Inc.   Report issue

For profit Phase 2
Founded: Baltimore MD United States (2007)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT02873819
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Gliknik Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

cyclophosphamide (cytoxan) (1 trial)

gl-0817 (1 trial)

poly-iclc (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Recurrence (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4